AP-238
Opioid designer drug
From Wikipedia, the free encyclopedia
AP-238 is an opioid designer drug related to drugs such as azaprocin and bucinnazine, with around the same potency as morphine.[2] It was first discovered in Italy in the 1960s but was never marketed,[3] subsequently appearing on the illicit market around 2020 and being detected in both Slovenia and the USA.[4][5]
Legal status
- UK: Under Psychoactive Substances Act
- US: The DEA is not of the opinion that AP-237 and derivatives are Controlled Substances, or analogues thereof. [1]
CAS Number
- (racemic) 4204-01-7 (racemic)
140924-11-4 (2R,6S enantiomer)
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| |
| CAS Number |
|
| PubChem CID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C18H26N2O |
| Molar mass | 286.419 g·mol−1 |
| 3D model (JSmol) | |
| |
| |